DK BIOCOM A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  12.2% 20.4% 12.5% 13.5% 12.7%  
Credit score (0-100)  21 5 17 16 17  
Credit rating  BB B BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  19.8 -11.7 -8.8 -0.0 24.6  
EBITDA  19.8 -11.7 -8.8 -0.0 24.6  
EBIT  19.8 -11.7 -8.8 -0.0 24.6  
Pre-tax profit (PTP)  19.8 -10.5 -11.9 -3.2 24.6  
Net earnings  15.5 -8.2 -9.3 -2.5 19.2  
Pre-tax profit without non-rec. items  19.8 -10.5 -11.9 -3.2 24.6  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  136 128 119 116 135  
Interest-bearing liabilities  327 327 327 327 302  
Balance sheet total (assets)  523 532 559 524 500  

Net Debt  -139 -145 -116 -112 -121  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  19.8 -11.7 -8.8 -0.0 24.6  
Gross profit growth  148.9% 0.0% 25.5% 99.9% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  523 532 559 524 500  
Balance sheet change%  5.1% 1.7% 5.1% -6.3% -4.4%  
Added value  19.8 -11.7 -8.8 -0.0 24.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 -1.0 -2.0 -3.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  3.9% -2.0% -1.6% -0.0% 4.8%  
ROI %  4.4% -2.3% -1.9% -0.0% 5.6%  
ROE %  12.1% -6.2% -7.5% -2.1% 15.3%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  26.0% 24.0% 21.2% 22.2% 27.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -700.9% 1,238.5% 1,324.5% 931,433.3% -494.0%  
Gearing %  240.3% 255.7% 275.6% 281.5% 223.1%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 1.0% 1.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.3 1.3 1.1 1.2 1.3  
Current Ratio  1.4 1.3 1.3 1.3 1.4  
Cash and cash equivalent  465.9 472.3 442.8 438.6 423.3  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  136.0 127.8 118.6 116.1 135.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0